Northgate Biopharma Advisory
Strategic advisory for US and international biopharmaceutical companies seeking successful, sustainable market entry and commercialization across Canada's uniquely complex healthcare environment.
Schedule a Discovery CallThe Canadian Market
Canada is not the US. It is not an EU member country. Organizations that approach Canada with assumptions built elsewhere often discover this too late — launching with a burdened P&L, giving away too much drug too early, struggling with reimbursement, and ultimately pulling back from a market that deserved better planning. These are the five realities that define success or failure.
US and international organizations often assume Canada mirrors their home market. This misread routinely leads to unsustainable launches, access failures, and difficult outcomes for patients who needed those therapies — with lasting impact on future pipeline plans.
Canada's system is a layered mosaic: federal (CDA-AMC, INESSS), pan-provincial (pCPA), provincial, robust private payer market, buying groups and institutional accounts — all requiring distinct strategies. CDA (formerly CADTH / pCODR) & INESSS health technology assessments shape access across public plans and must be strategically navigated early.
Canada's vast geography demands focused, access-driven resourcing. Payer contracts, population densities, healthcare infrastructure, and reimbursement timing vary dramatically by province. Strategic sequencing — knowing where to play and when — is critical to sustainable P&L outcomes.
In specialty, rare disease, and oncology, a Patient Support Program is not optional — it is a launch prerequisite. A negative patient experience in a competitive market is difficult to recover from; a positive one is a powerful differentiator. Knowing what to build, when, and where to invest makes the difference.
Medical affairs and market access must be integrated into P&L planning long before launch. Moving too early or too late through each access "gate" can make a brand non-viable or meaningfully attenuate growth. Timing is everything. Getting it right delivers a sustainable P&L, strong payback period, and earlier breakeven — turning Canada into the asset it should be.
What We Offer
From pre-launch strategy through commercialization, Northgate provides the insight and execution support your Canadian affiliate needs to succeed.
Senior commercial leadership without the full-time overhead. Embedded strategic and operational guidance for your Canadian affiliate at every stage of the lifecycle.
Rigorous assessment of the Canadian access landscape, revenue potential, and organizational requirements — so your entry is built on real knowledge, not assumptions.
End-to-end strategy across federal, CDA/pan-provincial, provincial, private, and institutional channels — including CADTH/CDA-AMC (and ACMTS equivalent) engagement and pCODR/CDA oncology submissions.
Building the full commercial architecture for launch: access pathway design, patient journey mapping, resource build-out, and P&L modeling aligned to Canadian realities.
Forecast modeling grounded in Canadian access timelines, payer demographics, and lifecycle realities — giving leadership the visibility needed for confident investment decisions.
Strategic sequencing of market expansion across provinces — knowing where to play first, when to scale, and how to optimize investment relative to access progress and population opportunity.
Designing PSPs that serve patients, satisfy access requirements, and fit the brand's commercial model — with the right investment in the right places at the right time.
How We Work
Every engagement begins with honest discovery — understanding your asset, your organization, and your ambitions. From there, we build a plan grounded in the Canadian realities that matter most.
A focused engagement to assess your asset's access landscape, competitive position, patient journey, and organizational readiness. We identify the gaps and the opportunities — with no false comfort about the challenges ahead.
Translating landscape insights into a clear, integrated market access and commercial strategy — including payer sequencing, CDA/CADTH engagement planning, provincial prioritization, PSP requirements, and P&L parameters.
Strategic support through launch and beyond: building teams, managing access negotiations, course-correcting on P&L performance, and ensuring every investment decision is tied to a clear access and commercial outcome.
Canada is a market with a full lifecycle — from launch through loss of exclusivity. Northgate helps organizations navigate each phase with disciplined investment reallocation, contract renegotiation, and sustained commercial performance.
The Advisor
Brent Serson is a Canadian biopharma commercial executive with over 25 years of leadership across commercial operations, market access, and strategic planning at Amgen Canada and Janssen. He has led specialty and rare disease franchises with full P&L accountability, directed national market access strategy through CADTH, pCPA, and provincial channels, and served as Chief of Staff to the VP/GM of a major Canadian affiliate — giving him an end-to-end view of what it takes to build and sustain a successful Canadian operation.
His CPA, CA designation brings financial discipline to commercial strategy — a combination rare in this space and consistently valued by global leadership teams assessing Canadian investment decisions.
View Full Profile on LinkedInGet In Touch
The right conversation about Canada can change the trajectory of your asset. Reach out to explore whether there's a fit.
Northgate Biopharma Advisory works with a select number of clients at a time, ensuring the depth of focus each engagement deserves.
📞 416.725.9016
✉️ brent@northgatebiopharma.ca
📍 Mississauga, Ontario, Canada